LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.
Bryan E JonesPatricia L Brown-AugsburgerKizzmekia S CorbettKathryn WestendorfJulian DaviesThomas P CujecChristopher M WiethoffJamie L BlackbourneBeverly A HeinzDenisa FosterRichard E HiggsDeepa BalasubramaniamLingshu WangRoza BidshahriLucas KraftYuri HwangStefanie ŽentelisKevin R JepsonRodrigo GoyaMaia A SmithDavid W CollinsSamuel J HinshawSean A TychoDavide PellacaniPing XiangKrithika MuthuramanSolmaz SobhanifarMarissa H PiperFranz J TrianaJorg HendleAnna PustilnikAndrew C AdamsShawn J BerensRalph S BaricDavid R MartinezRobert W CrossThomas W GeisbertViktoriya BorisevichOlubukola AbionaHayley M BelliMaren de VriesAdil MohamedMeike DittmannMarie SamanovicMark J MulliganJory A GoldsmithChing-Lin HsiehNicole V JohnsonDaniel WrappJason S McLellanBryan C BarnhartBarney S GrahamJohn R MascolaCarl L HansenEster FalconerPublished in: bioRxiv : the preprint server for biology (2020)
LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.